05:42 PM EST, 01/21/2025 (MT Newswires) -- Xilio Therapeutics ( XLO ) said late Tuesday that initial data from a phase 2 study of vilastobart in combination with atezolizumab to treat metastatic microsatellite stable colorectal cancer showed a 27% preliminary response rate in patients without liver metastases.

The drug combination also reduced levels of carcinoembryonic antigen and circulating tumor DNA along with improvement of symptoms, according to the company.

The data shows differentiated safety and tolerability profile and low incidence of immune-related adverse events, Xilio added.

Shares of Xilio Therapeutics ( XLO ) were down more than 7% in recent after-hours activity.